CVRx, Inc. (NASDAQ:CVRX – Get Free Report) has received an average recommendation of “Moderate Buy” from the seven brokerages that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $17.00.
A number of brokerages recently issued reports on CVRX. Lake Street Capital increased their target price on CVRx from $12.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Cantor Fitzgerald reiterated an “overweight” rating and set a $14.00 price objective on shares of CVRx in a report on Wednesday, October 23rd. William Blair raised shares of CVRx from a “market perform” rating to an “outperform” rating in a research report on Tuesday, January 14th. Canaccord Genuity Group lifted their price target on CVRx from $17.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Finally, Piper Sandler reissued an “overweight” rating and issued a $16.00 price objective (up from $13.00) on shares of CVRx in a research note on Wednesday, October 30th.
Hedge Funds Weigh In On CVRx
CVRx Stock Down 0.2 %
Shares of NASDAQ:CVRX opened at $16.81 on Friday. CVRx has a 1 year low of $6.40 and a 1 year high of $26.55. The company has a debt-to-equity ratio of 0.76, a current ratio of 11.32 and a quick ratio of 10.23. The business’s 50-day moving average is $14.67 and its 200-day moving average is $11.55. The company has a market capitalization of $407.81 million, a price-to-earnings ratio of -6.23 and a beta of 1.26.
CVRx (NASDAQ:CVRX – Get Free Report) last posted its quarterly earnings results on Tuesday, October 29th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.12). The company had revenue of $13.37 million during the quarter, compared to the consensus estimate of $13.28 million. CVRx had a negative net margin of 123.75% and a negative return on equity of 89.06%. During the same period last year, the firm posted ($0.43) earnings per share. Equities research analysts predict that CVRx will post -2.61 earnings per share for the current year.
CVRx Company Profile
CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.
Further Reading
- Five stocks we like better than CVRx
- Find and Profitably Trade Stocks at 52-Week Lows
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- CD Calculator: Certificate of Deposit Calculator
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- How to Invest in Biotech Stocks
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for CVRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVRx and related companies with MarketBeat.com's FREE daily email newsletter.